The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes [1] [2]
Your healthcare provider must evaluate your individual health situation and lactation plan before recommending treatment
Products are evaluated according to established quality-control procedures before release, helping ensure consistency, identity verification, and batch traceability
Researchers already experienced with GLP-1 compounds who understand titration, injection technique, and side effect management are better equipped to handle the complexity of a dual-peptide protocol
However, tirzepatide, the active ingredient in Mounjaro, is an FDA-approved weight loss medication under the brand name Zepbound
This was explicitly intended to boost Wegovy production (Wegovy being Novos obesity GLP-1 whose demand outpaced supply ( [11] ))